Biotech Safety Issue Downplayed

AMSTERDAM—In a session specifically devoted to safety, participants at the 4th European Congress of Biotechnology held here last month expressed virtually no concern about potential dangers during large-scale production of microbes containing recombinant DNA or following the release of such organisms into the environment. Kees Winkler from the University of Utrecht, in views that were not challenged, argued that because such bacteria—like those in the natural world—would have

Written byBernard Dixon
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Kees Winkler from the University of Utrecht, in views that were not challenged, argued that because such bacteria—like those in the natural world—would have to surmount various obstacles before gaining access to the body, there was no realistic prospect of their causing disease. He said that immune defenses and physical barriers to entry would prevent any adverse consequences.

In another session, Michael Teuber of West Germany's Bundesanstalt fur Milchforschung (Federal Center for Dairy Re search) in Kiel expressed greater caution. Discussing possible applications of genetically manipulated organisms in food, he reminded his audience that at least one bacterium likely to be widely used in the food industry, Streptococcus lactis, could donate genetic material in the form of plasmids to quite different genera. "We should be careful," Teuber suggested, "about introducing into S. lactis new genes that may be transferred to and be expressed in genera such as Clostridium and Leuconostoc."

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies